Published in

Coronaviruses, (01), 2020

DOI: 10.2174/2666796701999200713192912



Export citation

Search in Google Scholar

Amantadine Might be Used as a Drug for SARS-Cov-2 Treatment?

Journal article published in 2021 by Zeynep Gunes Ozunal, Sevki Sahin ORCID
This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Green circle
Preprint: archiving allowed
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO


: Coronavirus Disease 2019 (COVID-19) infection, the pandemics, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has any known effective radical pharmacotherapy, just supportive approach at present. Amantadine is a drug used in Parkinson’s disease and other parkinsonisms; and is known to increase indirectly dopamine by antagonistic effects at the N-methyl-D-aspartate (NMDA) receptor by increasing the release and blocking the reuptake of dopamine. Initially, amantadine was approved as an antiviral drug. We hypothesize that if amantadine considered both antiviral, immunological and neurostimulant effects might be useful in the supportive treatment of SARS-CoV-2 cases, especially those who developed acute respiratory failure with decreased vigilance and monitored in the intensive care unit. Further phase III clinical trials are needed.